9,900€
-11,61%
Echtzeit-Aktienkurs Bausch + Lomb Corp.
Bid:
Ask:
Echtzeit-Chart der Bausch + Lomb Corp. Aktie
Börsenkurse Bausch + Lomb Corp.
| gettex | - | - | - | - | 10,000€ | -1,48% |
| USA | - | - | - | - | 11,320$ | -9,66% |
| Börse Stuttgart | - | - | - | - | 9,900€ | -11,61% |
| New York | - | - | - | - | 11,400$ | 0,71% |
Fundamentaldaten der Bausch + Lomb Corp. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 4,79 Mrd. | -234,00 Mio. | -317,00 Mio. | -0,90 | - | - | 0,73 |
| 2023 [USD] | 4,15 Mrd. | -166,00 Mio. | -260,00 Mio. | -0,74 | - | - | 0,84 |
| 2022 [USD] | 3,77 Mrd. | 73,00 Mio. | 6,00 Mio. | 0,02 | - | 582,35 | 0,92 |
| 2021 [USD] | 3,77 Mrd. | 318,00 Mio. | 182,00 Mio. | 0,00 | - | - | - |
| 2020 [USD] | 3,41 Mrd. | 290,00 Mio. | -18,00 Mio. | 0,00 | - | - | - |
| 2019 [USD] | 3,78 Mrd. | 399,00 Mio. | 298,00 Mio. | 0,00 | - | - | - |
| 2018 [USD] | 3,67 Mrd. | 417,00 Mio. | 710,00 Mio. | 0,00 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Bausch + Lomb Corp. Aktie
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equ